Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI). (Q47224826)
Jump to navigation
Jump to search
scientific article published on 18 September 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI). |
scientific article published on 18 September 2017 |
Statements
1 reference
Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI). (English)
1 reference
John D Hainsworth
1 reference
David R Spigel
1 reference
Mark S Rubin
1 reference
Victor G Gian
1 reference
Dianna L Shipley
1 reference
Howard A Burris
1 reference
Rebecca A Kosloff
1 reference
Kent C Shih
1 reference
Raven Quinn
1 reference
F Anthony Greco
1 reference
18 September 2017
1 reference
1 reference
113
1 reference
79-84
1 reference